AM 251 and beta-Funaltrexamine reduce fat intake in a fat-preferring strain of mouse.
This experiment aimed to examine the role of the CB1 and Opioid mu receptors on fat preference by administering the CB1 inverse agonist AM 251 (5mg/kg i.p.) and the opioid mu antagonist beta-Funaltrexamine (15mg/kg s.c.) for 4 days to fat-preferring C57BL/6 mice fed a two-choice high-fat/low-fat diet. Both drugs were found to significantly reduce total energy intake, high-fat diet intake and fat preference during treatment.